Aurinia Pharmaceuticals (AUPH) FCF Margin (2015 - 2026)
Aurinia Pharmaceuticals posted quarterly FCF Margin of 41.85% for Q1 2026, up 3980.0% year-on-year from 1.03% in Q1 2025, and down 29.22% on a QoQ basis from 59.13% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) has 11 years of FCF Margin data on file, last reported at 41.85% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 3980.0% year-over-year to 41.85%; the trailing twelve-month figure through Mar 2026 stood at 55.87% (up 2999.0% YoY), and the FY2025 full-year result was 47.84%, up 2908.0% from the prior year.
- FCF Margin for Q1 2026 stood at 41.85%, down from 59.13% in the prior quarter.
- Across five years, FCF Margin topped out at 63.05% in Q2 2025 and bottomed at 216.53% in Q1 2022.
- The 5-year median for FCF Margin is 25.0% (2024), against an average of 6.36%.
- The widest annual swing landed in 2022, when FCF Margin surged 575502 bps; it then sank 520 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 36.28% in 2022, then fell by 14 bps to 31.07% in 2023, then surged by 62 bps to 50.21% in 2024, then grew by 18 bps to 59.13% in 2025, then slipped by 29 bps to 41.85% in 2026.
- The last three FCF Margin figures came in at 41.85% (Q1 2026), 59.13% (Q4 2025), and 60.41% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn | 41.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.85% |
| Dec 31, 2025 | 59.13% |
| Sep 30, 2025 | 60.41% |
| Jun 30, 2025 | 63.05% |
| Mar 31, 2025 | 2.05% |
| Dec 31, 2024 | 50.21% |
| Sep 30, 2024 | 25.00% |
| Jun 30, 2024 | 27.48% |
| Mar 31, 2024 | -37.00% |
| Dec 31, 2023 | 31.07% |
| Sep 30, 2023 | -24.16% |
| Jun 30, 2023 | -7.24% |
| Mar 31, 2023 | -93.05% |
| Dec 31, 2022 | 36.28% |
| Sep 30, 2022 | -27.61% |
| Jun 30, 2022 | -99.00% |
| Mar 31, 2022 | -216.53% |
| Dec 31, 2021 | -106.93% |
| Sep 30, 2021 | -298.29% |
| Jun 30, 2021 | -626.57% |
| Mar 31, 2021 | -5,971.55% |
| Dec 31, 2020 | 11.24% |
| Sep 30, 2020 | -93,158.62% |
| Jun 30, 2020 | 344.83% |
| Dec 31, 2019 | -100.00% |
| Dec 31, 2018 | 75.86% |
| Mar 31, 2016 | 1.75% |
| Sep 30, 2015 | -2,916.85% |
| Jun 30, 2015 | -3,054.55% |